| Literature DB >> 33103040 |
Ying Zhu1,2, Yu Liang1, Abdul Haseeb Khan1, Minghua Dong3, Yiqi Wan1, Zhichao Sun1, Yi Zeng4,5, Chao Nie6,7, Xiao-Li Tian1.
Abstract
OBJECTIVE: Human ABO blood groups are determined by the alleles A, B, and O (O01 and O02) of the ABO gene and have been linked to the risks for cardiovascular diseases and cancers that affect lifespan.We examined the genetic associations of the ABO gene and blood groups with longevity.Entities:
Keywords: ABO gene; centenarian; longevity; single nucleotide polymorphisms
Year: 2020 PMID: 33103040 PMCID: PMC7574633 DOI: 10.1002/agm2.12122
Source DB: PubMed Journal: Aging Med (Milton) ISSN: 2475-0360
The frequencies of ABO alleles
| Allele | SNP | Group | CN | CF | MN | MF | χ2 | OR | 95% CI |
|
|---|---|---|---|---|---|---|---|---|---|---|
|
| rs507666 | Total | 902 | 0.2049 | 980 | 0.2103 | 0.40 | 0.97 | 0.87‐1.07 | 0.53 |
| Male | 223 | 0.1956 | 356 | 0.2245 | 3.30 | 0.84 | 0.70‐1.01 | 0.07 | ||
| Female | 679 | 0.2082 | 624 | 0.2030 | 0.26 | 1.03 | 0.91‐1.17 | 0.61 | ||
|
| rs8176743 | Total | 899 | 0.2042 | 1016 | 0.2180 | 2.59 | 0.92 | 0.83‐1.02 | 0.11 |
| Male | 241 | 0.2114 | 341 | 0.2150 | 0.05 | 0.98 | 0.81‐1.18 | 0.82 | ||
| Female | 658 | 0.2017 | 675 | 0.2196 | 3.04 | 0.90 | 0.80‐1.01 | 0.08 | ||
|
| rs8176746 | Total | 918 | 0.2085 | 1039 | 0.2230 | 2.78 | 0.92 | 0.83‐1.02 | 0.10 |
| Male | 244 | 0.2140 | 345 | 0.2175 | 0.05 | 0.98 | 0.81‐1.18 | 0.83 | ||
| Female | 674 | 0.2066 | 694 | 0.2258 | 3.43 | 0.89 | 0.79‐1.01 | 0.06 | ||
|
| rs8176749 | Total | 916 | 0.2081 | 1032 | 0.2215 | 2.40 | 0.92 | 0.84‐1.02 | 0.12 |
| Male | 244 | 0.2140 | 344 | 0.2169 | 0.03 | 0.98 | 0.82‐1.18 | 0.86 | ||
| Female | 672 | 0.2060 | 688 | 0.2238 | 2.98 | 0.90 | 0.80‐1.01 | 0.08 | ||
|
| rs687289 | Total | 2576 | 0.5852 | 2646 | 0.5678 | 2.80 | 1.07 | 0.99‐1.17 | 0.09 |
| Male | 674 | 0.5912 | 888 | 0.5599 | 2.66 | 1.14 | 0.97‐1.33 | 0.10 | ||
| Female | 1902 | 0.5831 | 1758 | 0.5719 | 0.81 | 1.05 | 0.96‐1.16 | 0.37 | ||
|
| rs512770 | Total | 1103 | 0.2506 | 1156 | 0.2481 | 0.08 | 1.01 | 0.46‐1.25 | 0.78 |
| Male | 294 | 0.2579 | 381 | 0.2402 | 1.11 | 1.10 | 0.92‐1.31 | 0.29 | ||
| Female | 809 | 0.2480 | 775 | 0.2521 | 0.14 | 0.98 | 0.87‐1.10 | 0.71 | ||
|
| rs688976 | Total | 1103 | 0.2506 | 1156 | 0.2481 | 0.08 | 1.01 | 0.46‐1.25 | 0.78 |
| Male | 294 | 0.2579 | 382 | 0.2409 | 1.03 | 1.10 | 0.92‐1.31 | 0.31 | ||
| Female | 809 | 0.2480 | 774 | 0.2518 | 0.12 | 0.98 | 0.87‐1.10 | 0.73 | ||
|
| rs549446 | Total | 1104 | 0.2508 | 1157 | 0.2483 | 0.08 | 1.01 | 0.46‐1.12 | 0.78 |
| Male | 294 | 0.2579 | 383 | 0.2415 | 0.96 | 1.09 | 0.92‐1.30 | 0.33 | ||
| Female | 810 | 0.2483 | 774 | 0.2518 | 0.10 | 0.98 | 0.88‐1.10 | 0.75 |
Abbreviations: CF, frequency in centenarians; CI, confidence interval; CN, number of centenarians; MF, frequency in middle‐aged controls; MN, number of middle‐aged controls; OR, odds ratio; SNP, single nucleotide polymorphism.
The frequencies of ABO genotypes
| Genotype | Group | CN | CF | MN | MF | χ2 | OR | 95% CI |
|
|
|---|---|---|---|---|---|---|---|---|---|---|
|
| Total | 87 | 0.0395 | 105 | 0.0451 | 0.86 | 0.87 | 0.65‐1.17 | 0.36 | NT |
| Male | 19 | 0.0333 | 42 | 0.0530 | 2.99 | 0.62 | 0.36‐1.07 | 0.08 | NT | |
| Female | 68 | 0.0417 | 63 | 0.0410 | 0.01 | 1.02 | 0.72‐1.46 | 0.92 | NT | |
|
| Total | 290 | 0.1318 | 313 | 0.1343 | 0.07 | 0.98 | 0.82‐1.16 | 0.80 | NT |
| Male | 72 | 0.1263 | 108 | 0.1362 | 0.28 | 0.92 | 0.67‐1.25 | 0.60 | NT | |
| Female | 218 | 0.1337 | 205 | 0.1334 | 0.00 | 1.00 | 0.82‐1.23 | 0.97 | NT | |
|
| Total | 244 | 0.1109 | 230 | 0.0987 | 1.78 | 1.13 | 0.94‐1.38 | 0.18 | NT |
| Male | 61 | 0.1070 | 85 | 0.1072 | 0.00 | 1.00 | 0.71‐1.40 | 1.00 | NT | |
| Female | 183 | 0.1122 | 145 | 0.0943 | 2.72 | 1.21 | 0.96‐1.53 | 0.10 | NT | |
|
| Total | 93 | 0.0423 | 107 | 0.0459 | 0.36 | 0.92 | 0.69‐1.22 | 0.55 | NT |
| Male | 26 | 0.0456 | 44 | 0.0555 | 0.66 | 0.81 | 0.50‐1.33 | 0.42 | NT | |
| Female | 67 | 0.0411 | 63 | 0.0410 | 0.00 | 1.00 | 0.70‐1.41 | 1.00 | NT | |
|
| Total | 319 | 0.1449 | 329 | 0.1412 | 0.13 | 1.03 | 0.87‐1.22 | 0.72 | NT |
| Male | 85 | 0.1491 | 102 | 0.1286 | 1.18 | 1.19 | 0.87‐1.62 | 0.28 | NT | |
| Female | 234 | 0.1435 | 227 | 0.1477 | 0.11 | 0.97 | 0.79‐1.18 | 0.74 | NT | |
|
| Total | 219 | 0.0995 | 277 | 0.1189 | 4.36 | 0.82 | 0.68‐0.99 | 0.04 | |
| Male | 56 | 0.0982 | 81 | 0.1021 | 0.06 | 0.96 | 0.66‐1.38 | 0.81 | NT | |
| Female | 163 | 0.0999 | 196 | 0.1275 | 5.99 | 0.76 | 0.61‐0.95 | 0.01 | ||
|
| Total | 246 | 0.1118 | 236 | 0.1013 | 1.31 | 1.12 | 0.92‐1.34 | 0.25 | NT |
| Male | 68 | 0.1193 | 88 | 0.1110 | 0.23 | 1.08 | 0.78‐1.52 | 0.63 | NT | |
| Female | 178 | 0.1091 | 148 | 0.0963 | 1.41 | 1.15 | 0.91‐1.45 | 0.23 | NT | |
|
| Total | 360 | 0.1636 | 357 | 0.1532 | 0.91 | 1.08 | 0.92‐1.27 | 0.34 | NT |
| Male | 85 | 0.1491 | 110 | 0.1387 | 0.29 | 1.09 | 0.80‐1.47 | 0.59 | NT | |
| Female | 275 | 0.1686 | 247 | 0.1607 | 0.36 | 1.06 | 0.88‐1.28 | 0.55 | NT | |
|
| Total | 138 | 0.0627 | 143 | 0.0614 | 0.03 | 1.02 | 0.80‐1.30 | 0.85 | NT |
| Male | 45 | 0.0789 | 51 | 0.0643 | 1.09 | 1.25 | 0.82‐1.87 | 0.30 | NT | |
| Female | 93 | 0.0570 | 92 | 0.0599 | 0.12 | 0.95 | 0.70‐1.28 | 0.73 | NT | |
|
| Total | 189 | 0.0859 | 212 | 0.0910 | 0.37 | 0.94 | 0.76‐1.15 | 0.54 | NT |
| Male | 49 | 0.0860 | 71 | 0.0895 | 0.05 | 0.96 | 0.66‐1.39 | 0.82 | NT | |
| Female | 140 | 0.0858 | 141 | 0.0917 | 0.34 | 0.93 | 0.73‐1.18 | 0.56 | NT |
Abbreviations: CF, frequency in centenarians; CI, confidence interval; CN, number of centenarians; MF, frequency in middle‐aged controls; MN, number of middle‐aged controls; NT, not tested; OR, odds ratio; P corr, P value after Bonferroni correction.
The frequencies of ABO blood types
| Blood type | Group | CN | CF | MN | MF | χ2 | OR | 95% CI |
|
|
|---|---|---|---|---|---|---|---|---|---|---|
| A | Total | 621 | 0.2821 | 648 | 0.2781 | 0.09 | 1.02 | 0.90‐1.16 | 0.76 | NT |
| Male | 152 | 0.2667 | 235 | 0.2963 | 1.44 | 0.86 | 0.68‐1.10 | 0.23 | NT | |
| Female | 469 | 0.2876 | 413 | 0.2687 | 1.40 | 1.10 | 0.94‐1.28 | 0.24 | NT | |
| B | Total | 631 | 0.2867 | 713 | 0.3060 | 2.03 | 0.91 | 0.80‐1.04 | 0.15 | NT |
| Male | 167 | 0.2930 | 227 | 0.2863 | 0.07 | 1.03 | 0.82‐1.31 | 0.79 | NT | |
| Female | 464 | 0.2845 | 486 | 0.3162 | 3.79 | 0.86 | 0.74‐1.00 | 0.05 | ||
| O | Total | 744 | 0.3380 | 736 | 0.3159 | 2.52 | 1.11 | 0.98‐1.25 | 0.11 | NT |
| Male | 198 | 0.3474 | 249 | 0.3140 | 1.68 | 1.16 | 0.93‐1.46 | 0.20 | NT | |
| Female | 546 | 0.3348 | 487 | 0.3169 | 1.16 | 1.09 | 0.93‐1.26 | 0.28 | NT | |
| AB | Total | 189 | 0.0859 | 212 | 0.0910 | 0.37 | 0.94 | 0.76‐1.15 | 0.54 | NT |
| Male | 49 | 0.0860 | 71 | 0.0895 | 0.05 | 0.96 | 0.66‐1.39 | 0.82 | NT | |
| Female | 140 | 0.0858 | 141 | 0.0917 | 0.34 | 0.93 | 0.73‐1.18 | 0.56 | NT |
Abbreviations: CF, frequency in centenarians; CI, confidence interval; CN, number of centenarians; MF, frequency in middle‐aged controls; MN, number of middle‐aged controls; NT, not tested; OR, odds ratio; P corr, P value after Bonferroni correction.
Figure 1Flowchart representing the study selection process for the meta‐analysis.
Characteristics, ABO blood types distribution, and NOS scores of included studies
| First Author, YRef. | Sturgeon, 1969 | Coppola, 2003 | Shimizu, 2004 | Mengoli, 2015 | Franchini, 2016 | Current study, 2020 | |
|---|---|---|---|---|---|---|---|
| Country | Turkey | Italy | Japan | Italy | Italy | China | |
| Exposure measures | Serological methods | Blood test | Blood test | Electronic clinical records | Standard micro‐column agglutination technology | Genotyping by SNPs | |
| Number of centenarians | 50 | 74 | 269 | 252 | 165 | 2201 | |
| A/non‐A | Cases | 22/28 | 92/177 | 108/144 | 55/110 | 621/1580 | |
| Controls | 47/63 | 2759/4394 | 2145/2880 | 2086/2977 | 648/1682 | ||
| B/non‐B | Cases | 11/39 | 79/190 | 22/230 | 14/151 | 631/1570 | |
| Controls | 20/90 | 1570/5583 | 575/4450 | 541/4522 | 713/1617 | ||
| O/non‐O | Cases | 11/39 | 32/42 | 76/193 | 110/142 | 93/72 | 744/1457 |
| Controls | 37/73 | 39/71 | 2153/5000 | 2087/2938 | 2201/2862 | 736/1594 | |
| AB/non‐AB | Cases | 6/44 | 22/247 | 12/240 | 3/162 | 189/2012 | |
| Controls | 6/104 | 671/6482 | 218/4807 | 235/4828 | 212/2118 | ||
| NOS | 7 | 8 | 8 | 8 | 7 | 8 | |
Abbreviations: NOS, Newcastle‐Ottawa Scale; SNPs, single nucleotide polymorphisms.
Figure 2Forest plots of ABO blood types and longevity: (A) blood type A and longevity, (B) blood type B and longevity, (C) blood type O and longevity, (D) blood type AB and longevity.
Summary of longevity with ABO blood group association
| First author, YearRef. | Population source | Case number/Mean age (y) | Control number/Mean age (y) |
| Conclusion |
|---|---|---|---|---|---|
| Murray, 1961 | United Kingdom | 281/71.7 | 352/75.8 | <0.025 | A decrease in blood group O and an increase in group A in the healthy group compared with the geriatric group. |
| Sturgeon, 1969 | Turkey | 50/105 | 110/36 | >0.05 | No association between ABO blood groups and longevity was found. |
| Shimizu, 2004 | Japan | 269/101.2 | 7153/54.8 | 0.04 | Blood type B individuals might live longer. |
| Vasto, 2011 | Italy | 38/(100‐107) | 59/(45‐65) | >0.05 | No association between ABO blood groups and longevity was found. |
| Brecher and Hay, 2011 | United States | 772 death patients/(0‐97) | <0.01 | Instead of a marker for longevity, blood type B might be a marker for earlier death. |
Summary of subjects with ABO allelic and/or genotypic association
| First author, YearRef. | Method | Associated allele or genotype | Subject | Population source | Case number/Mean age (y) |
| Conclusion |
|---|---|---|---|---|---|---|---|
| Barbalic, 2010 | GWAS |
| sICAM‐1 | ARIC,a CHS,b FHS,c RSd | 829/55.8,a 6845/49.4,b 600/>70.3,c 1487/72.8d | 9.9E‐07 | Both sP‐selectin and sICAM‐1 were associated with |
| Barbalic, 2010 | GWAS |
| sP‐selectin | ARIC,a FHS,c RSd | 673/56.6,a 3036/>61.0,c 406/69.4d | 1.8E‐11 | |
| de Paula Sabino, 2014 | Case study |
| IS | HUUH | 86/36 | <0.001 |
|
| Tirado, 2005 | Case study |
| VTE | THU | 250/47.6 | <0.001 | Non‐O blood groups, especially with |
| Nakao, 2011 | Case study | Allele | GC | ACCH | 703/(20‐79) |
| Allele |
| Souto, 2000 | Combined linkage and association test |
| vWF and FVIII | GAIT Project | 397/37.7 | vWF:1E‐7, FVIII: 8.2E‐6 |
|
| Melzer, 2008 | GWAS |
| TNF‐alpha | InCHIANTI | 1200/68.4 | 6.80E‐40 | An assay‐specific association appeared between ABO blood group and TNF‐alpha levels. |
| Paterson, 2009 | GWAS |
| sE‐selectin | DCCT and EDIC | 685/51.8 | 3.7E‐29 |
|
| Antwi, 2018 | Pooled analysis |
| PC | PanC4,e PanScanf | 2414/65.1,e 1268/67.2f | < 0.0001,e 0.002f | Genotype‐derived non‐O blood type was associated with increased pancreatic cancer risk. |
Abbreviations: ACCH, Aichi Cancer Center Hospital (Nagoya, Japan); ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study; DCCT, Diabetes Control and Complications Trial; EDIC, Epidemiology of Diabetes Intervention and Complications; FHS, Framingham Heart Study; FVIII, factor VIII; GAIT, Genetic Analysis of Idiopathic Thrombophilia; GC, gastric cancer; GWAS, genome‐wide association study; HUUH, Hematology Unit of the University Hospital (Federal University of Minas Gerais, Belo Horizonte MG); InCHIANTI, A population‐based study of persons living in the Chianti geographic area (Tuscany, Italy); IS, ischemic stroke; PanC4, Pancreatic Cancer Case‐Control Consortium; PanScan, Pancreatic Cancer Cohort Consortium; PC, pancreatic cancer; RS, Rotterdam Study; sE‐selectin, soluble E‐selectin; sICAM‐1, soluble intercellular adhesion molecule‐1; sP‐selectin, soluble P‐selectin; THU, thrombosis and hemostasis units from local hospitals (Spain); TNF‐alpha, tumor necrosis factor‐alpha; VTE, venous thromboembolism; vWF, von Willebrand factor. The superscript symbols a‐f in the Population source column correspond to those in the next column.